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A B S T R A C T
The lipophilic character of peptides can be tremendously improved by hydrophobic ion pairing (HIP) with
counterions to be efficiently incorporated into lipid-based nanocarriers (NCs). Herein, HIPs of exenatide with the
cationic surfactant tetraheptylammonium bromide (THA) and the anionic surfactant sodium docusate (DOC)
were formed to increase its lipophilicity. These HIPs were incorporated into lipid based NCs comprising 41%
Capmul MCM, 15% Captex 355, 40% Cremophor RH and 4% propylene glycol. Exenatide-THA NCs showed a log
Dlipophilic phase (LPh)/release medium (RM) of 2.29 and 1.92, whereas the log DLPh/RM of exenatide-DOC was 1.2 and
−0.9 in simulated intestinal fluid and Hanks’ balanced salts buffer (HBSS), respectively. No significant hemo-
lytic activity was induced at a concentration of 0.25% (m/v) of both blank and loaded NCs. Exenatide-THA NCs
and exenatide-DOC NCs showed a 10-fold and 3-fold enhancement in intestinal apparent membrane perme-
ability compared to free exenatide, respectively. Furthermore, orally administered exenatide-THA and exena-
tide-DOC NCs in healthy rats resulted in a relative bioavailability of 27.96 ± 5.24% and 16.29 ± 6.63%,
respectively, confirming the comparatively higher potential of the cationic surfactant over the anionic surfac-
tant. Findings of this work highlight the potential of the type of counterion used for HIP as key to successful
design of lipid-based NCs for oral exenatide delivery.
1. Introduction
Exenatide, a 39-amino-acid peptide (molecular mass: 4.186 kDa),
shares a 50% sequence homology with the native GLP-1 with the sub-
stitution of amino acid Arg with Gly at the 2nd position providing re-
sistance against DPP-4 and thus a longer half-life [1]. This GLP-1 ana-
logue is marketed as Byetta® that is administered twice daily through
subcutaneous (s.c.) injection, and as Bydureon® that is a sustained re-
lease product s.c. injected once-weekly [2]. Since frequent s.c. injection
can adversely affect patients’ adherence to the treatment, patient-
friendly non-invasive delivery systems are highly on demand. The oral
route is regarded as the most preferable choice due to high patient
compliance in addition to mimicking the physiological GLP-1 secretion
from the intestine to the systemic circulation [3–5]. Oral GLP-1 de-
livery, however, is limited by mainly two barriers: the harsh environ-
ment in the gastrointestinal tract (GIT) and the absorption membrane
barrier [6,7]. In September 2019 Novo Nordisk's semaglutide tablet
(Rybelsus®) entered the global market as the first orally administered
GLP-1 analogue formulation containing sodium N-(8-[2–hydro-
xybenzoyl] amino) caprylate as absorption enhancer. The absolute
bioavailability of semaglutide, however, was estimated to be just 0.4%-
1% after oral administration underlining the great dimension of these
barriers [8].
Among the various technologies having been developed to over-
come the obstacles limiting oral peptide delivery [9,10], the formation
of hydrophobic ion pairs (HIPs) proved to be promising as this can
increase the lipophilic character of hydrophilic peptide drugs and thus
enhance their permeability of lipophilic membranes [11,12]. Because of
a limited stability of HIPs in the GI tract, the incorporation of HIPs into
lipophilic carrier systems is advantageous [13–15]. In addition to a
protective effect towards presystemic metabolism [16–18], lipid-based
nanocarrier systems in particular proved to be able to facilitate mucus
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permeation and to enhance the cellular uptake of peptides [19–22].
Various anionic surfactants were previously investigated by our
research group regarding the formation of HIPs with exenatide, and
exenatide-DOC ion pairs in a molar ratio of 1:4 were identified as most
promising showing a relative oral bioavailability of 14% [23].
As exenatide bears not just cationic but also anionic substructures, it
can likely form HIPs with cationic surfactants as well. Considering that
there are four cationic amino acids but even six anionic amino acids on
exenatide available for ion pairing as illustrated in Fig. 1, cationic
surfactants might even show higher potential. Whether HIPs formed
with cationic or anionic surfactant provide a higher bioavailability of
exenatide, however, has not been investigated so far.
The aim of this research reported here was to investigate the po-
tential of a cationic surfactant in forming HIPs with exenatide and to
compare its efficacy with the most promising anionic surfactant doc-
usate (DOC) [11,23]. Because of its permanent cationic charge and
highly lipophilic character, tetraheptylammonium bromide (THA)
having already shown potential for HIPs formation in a previous in vivo
study was chosen [24]. Firstly, HIPs of exenatide-THA were optimized
and the zeta potential change during HIPs formation was examined.
The most promising exenatide-THA and exenatide-DOC HIPs were in-
corporated in a lipid-based nanocarrier that was characterized re-
garding droplet size, polydispersity index (PDI) and zeta potential.
Furthermore, safety and intestinal permeability of this delivery system
was investigated, followed by pharmacokinetic studies in rats to eval-
uate their efficacy.
2. Materials and methods
2.1. Materials
Exenatide was purchased from Chemos GmbH (Germany) . Capmul
MCM EP (mono/diglycerides of caprylic acid, HLB 5–6) and Captex 355
(caprylic/capric triglycerides) were supplied by Abitec (USA).
Cremophor RH (polyoxyl hydrogenated 40 castor oil, HLB 14–16), so-
dium docusate and tetraheptylammonium bromide were purchased
from Sigma-Aldrich (Austria). Minimum Essential Medium Eagle
(MEM) and Dulbecco's phosphate buffered saline (DPBS) were supplied
from Biochrom GmbH, Berlin, Germany. Exendin-4 fluorescent ELISA
kit was purchased from Phoenix Pharmaceuticals, Inc. (Burlingame,
Fig. 1. The chemical structure of (A) exenatide-tetraheptylammonium bromide (THA) ion pairs, (B) exenatide-docusate (DOC) ion pairs.
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CA). Hanks’ Balanced Salts (HBSS), propylene glycol and all other re-
agents and solvents were purchased from Sigma -Aldrich (Austria).
2.2. Methods
2.2.1. Hplc
Reversed-phase HPLC (Hitachi Chromaster HPLC-system equipped
with 5430 photodiode array UV detector, Tokyo, Japan) method was
developed in our lab to quantify exenatide. A Nucleosil® C18 100–5
column (5 μm, 250*4 mm, Phenomenex, USA) was used as stationary
phase. The mobile phase consisted of 0.1% TFA in water (eluent A) and
80% acetonitrile with 0.1% TFA (eluent B), and was pumped in a linear-
gradient mode from 58:42 (A:B, v/v) to 24:76 (A:B, v/v) at a flow rate
of 0.75 ml/min over 22 min. The column temperature was set to 40 °C.
Twenty microliters of sample volume was injected. The wavelength of
UV detection was 278 nm. Retention time of exenatide was 16.5 min
and the regression coefficient (R2) of calibration curve was 0.999
proving high linearity.
2.2.2. Hydrophobic ion-pairing of exenatide with THA and DOC
Exenatide acetate aqueous solution was prepared in a concentration
of 2 mg/ml and pH was adjusted with 0.1 M NaOH to 8.0. Increasing
amounts of THA were dissolved in 1 ml of demineralized water: me-
thanol and added slowly and dropwise to 1 ml of the exenatide solution
under light shaking. Exenatide to THA ratios of 1:1, 1:2, 1:4, 1:6, 1:8,
1:10 and 1:12 were tested. Exenatide-DOC ion pairs were prepared as
previously described [23], where the pH of an exenatide solution of
2 mg/ml was adjusted to 3.0 with 2 M HCl followed by the addition of
an equal volume of DOC aqueous solution slowly and dropwise to ex-
enatide solution under light shaking. Exenatide to DOC molar ratios of
1:1, 1:2, 1:4 and 1:6 were tested.
HIPs were collected by centrifugation for 5 min at 13400 rpm
(MiniSpin®, Eppendorf Austria GmbH) and washing 3 times with water.
The supernatant that contained the remaining amount of dissolved
exenatide was analyzed by HLPC as described above to calculate the
precipitation efficiency using the following equation:
= −
×
Precipitation efficiency
peptide concentration after HIP peptide concentration
before HIP
(%)
100 ( /
100)
Zeta potential of HIPs with surfactant was determined with
Zetasizer Nano ZSP (Malvern Instruments, Worcestershire, UK).
Precipitated HIPs were frozen, freeze-dried at −30 °C and 3–5 mTorr
(Christ Gamma 1–16 LSC Freeze dryer) and stored at−20 °C for further
use.
2.3. Development and characterization of lipid-based nanocarriers
HIPs with THA were prepared in a molar ratio of 1:8 (exenatide:
THA) at pH 8. HIPs with DOC were prepared in a molar ratio of 1:4
(exenatide: DOC) at pH 4 as previously described by our research group
[23]. Lipid-based nanocarriers were formed by dissolving 2 mg of HIPs
having been prepared as described above in 4 mg of propylene glycol
(PG) by stirring for 2 min and homogenizing (1500 rpm) for 10 min at
room temperature (Eppendorf ThermoMixer®, Hamburg, Germany).
This was followed by addition of 41 mg of Capmul MCM (oil), 40 mg of
Kolliphor RH (surfactant) and 15 mg of Captex 355 (oil) and homo-
genizing the mixture (1500 rpm) after the addition of each component
(Eppendorf ThermoMixer®, Hamburg, Germany).
To determine the maximum payload of HIPs and exenatide in the
formulation, the preconcentrate was analyzed by HPLC. Furthermore,
size, polydispersity index and zeta potential of NCs having been dis-
persed in demineralized water (1:100) were measured via Zetasizer
Nano ZSP (Malvern Instruments, Worcestershire, UK). Aiming to assess
the stability of the NCs, droplet size, PDI and zeta potential were
measured after 4 h and one week.
2.4. Determination of log Dlipophilic phase (LPh)/release medium (RM) of exenatide-
THA and exenatide-DOC
The release characteristics of exenatide-THA and exenatide-DOC
from the nanocarriers were evaluated by determining the distribution
of the ion pairs between the lipophilic phase of the NCs and the release
medium (log DLPh/RM) [25,26]. Lyophilized exenatide-THA (molar ratio
1:8) and exenatide-DOC (molar ratio 1:4) were dispersed in simulated
intestinal fluid (50 mM phosphate buffer pH 6.8), HBSS and the lipo-
philic phase of the NC. After stirring for 3 h at 1000 rpm, each sus-
pension was centrifuged for 5 min at 13,400 rpm. The solubility of HIPs
in each release medium (CRM) and the lipophilic phase of the nano-
carrier (CLPh) was calculated by analyzing the supernatant by HPLC.
Log DLPh/RM of HIPs was calculated according to the following equation:
=LPh RM
LPh
logD log C
C
/ RM
2.5. In vitro hemolysis assay
In vitro hemolysis assay with exenatide-THA and exenatide-DOC as
well as blank NCs was performed according to a previously reported
protocol [27]. The dilution of 0.556 ml of human whole blood with
1.944 ml of sterile Dulbecco’s PBS pH 7.4 was performed. Subsequently,
1 ml of this suspension was diluted with 49 ml of sterile Dulbecco’s PBS
pH 7.4.
First, 50 µl of NCs was added to 1 ml of diluted blood to the final
concentration of 0.1%, 0.25% and 0.5% (m/v). This was followed by an
immediate shaking of the mixtures on thermomixer for 2 h at 300 rpm
and 37 °C and additionally homogenized by inversion during the in-
cubation. Then, the mixtures were centrifuged at 503*g for 5 min at
5 °C. Tecan infinite M200 plate reader was used to read the absorbance
of the supernatants at a wavelength of 420 nm. Triton-X-100 1% (m/v)
in MEM and sterile Dulbecco’s PBS pH 7.4 served as positive and ne-
gative control, respectively.
The percentage of hemolysis (H %) was calculated as follows:
=
−
−
H
Abs test Abs neg
Abs pos Abs neg
(%)
( ) ( )
( ) ( )
where Abstest is absorbance of the test sample, Absneg is absorbance of
PBS (negative control) and Abspos is absorbance of Triton-X-100 (posi-
tive control).
2.6. Ex vivo permeability study
The ex-vivo permeability study was carried out on fasted rats with a
body weight of 200–250 g. Rats were sacrificed and the freshly excised
small intestine was preincubated in HBSS buffer for 30 min before being
cut into strips of 2 cm mounted in Ussing-type chambers. The apical and
basolateral sides were filled with 1 ml of HBSS pH 6.8 and incubated for
30 min in a water bath at 37 °C. Then, HBSS was replaced by fresh
incubation medium at apical side and by the following test samples: (1)
0.25% of exenatide-THA-NCs, (2) 0.6% of exenatide-DOC NCs and (3)
8 µg /ml of exenatide solution in HBSS at the apical side.
Aliquots of 200 µl were withdrawn from the basolateral side at 1, 2,
and 3 h and replaced with an equal volume of fresh HBSS preincubated
at 37 °C. Exenatide concentration in the aliquots was quantified by
fluorescent ELISA immunoassay (FEK-070-94; Phoenix
Pharmaceuticals, Inc., USA) following the manufacturer’s instructions.
The absorbance was read at 450 nm using a microplate reader (Spark
Multimode microplate reader, Tecan). Values are presented as
means ± SD (n = 3).
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2.7. In vivo study
Male Sprague-Dawley rats with a body weight of 200–250 g were
supplied by Janvier Labs (Saint Berthevin, France) and the in vivo study
was approved by the Ethical Committee of Austria and performed ac-
cording to the principles of Laboratory Animal Care.
Rats were fasted 2 h prior to drug administration and 6 h thereafter
but had free access to water during the entire experiment. Rats were
divided into four groups (n = 5). A dose of 50 µg/kg body of exenatide
solution was administered to the first group via subcutaneous injection.
The second group was the negative control group where exenatide so-
lution was orally administered at a dose of 300 µg/kg body. The third
and fourth group received 300 µg/kg body weight of exenatide-THA
and exenatide-DOC NC formulation via oral gavage, respectively. The
formulations were diluted with water (1:2) before administration.
Blood samples (100 µl) were collected from the tail vein before drug
administration and at predetermined time points after dosing.
Following the centrifugation of the blood samples for 5 min at 2000*g
and 4 °C, the serum was separated and stored at −80 °C for further
analysis. Exenatide concentration was measured by fluorescent ELISA
immunoassay (FEK-070-94; Phoenix Pharmaceuticals, INC., USA). The
absorbance was read at 450 nm using a microplate reader (Spark
Multimode microplate reader, Tecan).
The relative bioavailability (BAR) of exenatide after oral adminis-
tration was calculated using the following equation:
=
∗
∗
∗BA (%) AUC (oral) Dose (S.C.)
AUC (S.C.) Dose (oral)
100R
2.8. Statistical analysis
The GraphPad Prism software (version 5.0.1) was used to conduct
the statistical data analysis, performing Analysis of Variance (ANOVA)
followed by Bonferroni test with p < 0.05 as the minimal level of
significance. All values are shown as means ± SD.
3. Results
3.1. Hydrophobic ion-pairing of exenatide with cationic/anionic surfactants
The cationic surfactant THA and the anionic surfactant DOC were
capable of forming HIPs with the anionic and cationic amino acids of
exenatide via non-covalent ionic interactions (Fig. 1). The addition of
THA or DOC to the exenatide solution caused an immediate precipita-
tion indicating the formation of HIPs. Different exenatide to surfactant
ratios were evaluated as illustrated in Fig. 2. The more surfactant was
added to exenatide, the more HIPs were formed until the maximum
precipitation efficiency of 95.3 ± 4.02% at molar ratio of 1:8 (ex-
enatide: THA), whereas a maximum of 100% was reached in case of
DOC at molar ratio of 1:4 (exenatide: DOC). Higher concentrations of
surfactant led to a lower amount of formed ion pairs. This observation
was previously also reported for other surfactants [11] and could be
due to the formation of micelles that re-dissolve the ion pair complex
[28].
3.2. Zeta potential of exenatide-surfactant HIPs
The zeta potential of HIPs having been formed at different molar
ratios of exenatide to surfactant was tested in order to evaluate the
surface charge of the complexes. Fig. 3A shows that the negative charge
of exenatide at pH 8.0 decreased with the increase in THA having been
bound to the peptide drug reaching the lowest negative zeta potential at
a molar ratio of 1:10 (exenatide: THA). At a higher molar ratio, the THA
level could exceed the critical micellar concentration (CMC) and the
resulting formation of micelles can explain the increase in negative zeta
potential due to the solubilizing effect of the excess of THA. The
formation of these micelles could attribute to reduce the amount of THA
being bound to the surface of exenatide causing a higher negative
charge. In case of exenatide-DOC, a shift in zeta potential toward ne-
gative values was observed where the positive charge of exenatide at
pH 3.0 decreased with higher molar ratio (exenatide:DOC) reaching
almost 0 mV at a molar ratio of 1:4 (Fig. 3B).
4. Development and characterization of the nanocarrier system
The maximum payload of exenatide-THA and exenatide-DOC that
could be dissolved in the lipophilic phase of the NCs was 0.54% and
0.17%, respectively. This payload was used to prepare NCs for further
evaluation.
Small droplet size (< 30 nm) with low PDI value was determined
for blank and loaded NCs (Table 1). The surface charge of exenatide-
THA loaded NCs was positive whereas negative values were measured
in case of exenatide-DOC loaded NCs. This observation can be explained
by the cationic character of THA and the anionic character of DOC.
Both blank and loaded NCs showed sufficient stability for one week
regarding the droplet size, PDI and zeta potential as shown in Table1.
4.1. Determination of log D of exenatide-THA and exenatide-DOC
It was previously reported that the drug release from lipid-based
NCs formulation depends on a simple diffusion process from a lipophilic
liquid phase into an aqueous liquid phase that occurs within a few
seconds [26]. As the released HIPs are absorbed from the membrane,
more HIPs will diffuse out of the nanodroplets until equilibrium is
reached again. Since drug release is controlled by the partition coeffi-
cient of HIPs between the lipophilic phase (LPh) and the release
medium (RM) that should mimic gastrointestinal conditions, log DLPh/
RM was determined in two different aqueous media [25,26]. Log DLPh/
RM of exenatide-THA was 2.29 and 1.92, whereas the log DLPh/RM of
exenatide-DOC was 1.2 and −0.9 in simulated intestinal fluid and
HBSS, respectively. These log D values proved that THA is capable of
forming more pronounced hydrophobic complexes than DOC.
4.2. Cytocompatibility
The in vitro hemolysis assay on human erythrocytes can be used as a
rapid and reliable method to evaluate the effect of drug delivery
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Fig. 2. Precipitation efficiency of exenatide (2 mg/mL) with THA and DOC at
different molar ratios. The precipitated exenatide-surfactant ion pairs were
centrifuged and the remaining amount of exenatide in supernatant was quan-
tified by HPLC. Data are presented as mean ± SD (n = 3).
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systems on cell membranes [27,29]. In comparison to other cell types,
the cell membrane of erythrocytes is very fragile. NCs loaded with
different concentrations of either exenatide-THA or exenatide-DOC
were tested regarding their hemolytic activity and compared to blank
NCs. Fig. 4 displays the hemolysis caused by increasing concentrations
of blank and loaded NCs. Compared to NCs loaded with exenatide-THA,
NCs loaded with exenatide-DOC showed higher toxicity as concluded
from the hemolytic activity reaching more than 90% at a concentration
of 0.5% (m/v) of this formulation.
4.3. Ex-vivo permeability study
Results presented in Fig. 5 clearly demonstrated that the intestinal
permeation of exenatide incorporated in NCs was enhanced in com-
parison to the free peptide. Moreover, results proved the superiority of
exenatide-THA NCs when compared to exenatide-DOC NCs. This out-
come provides evidence for the crucial role of the type of HIPs in-
corporated in NCs in enhancing permeability across the intestinal
mucus gel layer and epithelial barrier strongly limiting oral peptide
uptake.
Fig. 3. The shift in zeta potential values of (A) exenatide-THA HIPs formed at pH 8.0 in different molar ratios, (B) exenatide-DOC HIPs formed at pH 3.0 in different
molar ratios. Data are presented as mean ± SD (n = 3).
Table 1
Droplet Size, polydispersity index (PDI), zeta potential of blank NCs, exenatide-
THA N.
Droplet Size (nm) PDI Zeta potential (mV)
0 h
Exenatide-THA NCs 25.71 ± 2.48 0.24 ± 0.48 10.11 ± 1.07
Exenatide-DOC NCs 24.55 ± 3.2 0.25 ± 0.046 20 ± 2.2-
Blank NCs 24.11 ± 2.26 0.13 ± 0.04 3.42 ± 0.47-
4 h
Exenatide-THA NCs 23.64 ± 2.75 0.05 ± 0.03 5.5 ± 0.85
Exenatide-DOC NCs 25.17 ± 5.22 0.2 ± 0.07 12.67 ± 2.08-
Blank NCs 26.24 ± 1.61 0.04 ± 0.02 2.5 ± 1.07-
1 week
Exenatide-THA NCs 22.49 ± 4.55 0.081 ± 0.11 9.24 ± 3.42
Exenatide-DOC NCs 20.2 ± 0.63 0.11 ± 0.05 9.37 ± 0.15-
Blank NCs 27.07 ± 1.76 0.13 ± 0.06 7.3 ± 0.38-
Cs and exenatide-DOC NCs in water over time. Data are presented as
mean ± SD (n = 3).
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Fig. 4. Cytotoxicity of different concentrations of blank NCs, exenatide-THA
NCs, exenatide-DOC NCs. Hemolysis assay was conducted with human red
blood cells (RBC). Data are presented as mean ± SD (n = 3).
Fig. 5. Evaluation of ex vivo permeability of exenatide across rat intestinal
mucosa following the treatment with free exenatide solution, exenatide-THA
NCs or exenatide-DOC NCs. Values are presented as means ± SD (n = 3).
Statistical analysis: Analysis of Variance (ANOVA) followed by Bonferroni test,
* p < 0.05, ** P < 0.01.
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4.4. In-vivo study
As illustrated in Fig. 6, s.c. injection of free exenatide solution eli-
cited a maximum serum level at 1 h after administration being in good
agreement with previous reported studies [30]. The orally administered
free exenatide solution could not provide any systemic uptake of the
drug. In contrast, high exenatide serum levels were observed after oral
administration of exenatide-THA and exenatide-DOC NCs reaching
maximum after 3 h. The relative oral bioavailability (versus s.c.) of
exenatide-THA NCs (Table 2) was 27.96 ± 5.24%. This is to our
knowledge the highest so far achieved oral bioavailability of a GLP-1
analogue emphasizing the great potential of hydrophobic ion pairing
for oral peptide delivery. The oral bioavailability of the exenatide-THA
ion pair was almost 2-fold higher than that of the exenatide-DOC ion
pair (Table 2). These results were in good accordance with the per-
meation behaviour of these HIPs on the intestinal mucosa as shown in
Fig. 5 demonstrating a 3-fold higher Papp of the exenatide-THA ion pair.
5. Discussion
Despite the advances in peptide and protein delivery, the oral de-
livery of GLP-1 analogues like exenatide is still an elusive goal being
limited by mainly the enzymatic barrier, mucus barrier and low
membrane permeability. In this study, exenatide was incorporated in
lipid-based NCs since it has been proven in many previous studies that
lipid-based NCs can overcome the above mentioned hurdles for oral
peptide delivery [7,16,22]. Hydrophobic ion pairing was applied before
incorporation in NCs to sufficiently reduce hydrophilicity of the peptide
by masking its ionic substructures with bulky lipophilic counter-ions
[17,21,31]. The isoelectric point (IP) of exenatide is 4.86 [32]. At a pH
above this IP the drug bears six anionic substructures at position 3, 9,
15, 16, 17 and 24 in its amino acid sequence being available for ion
pairing with the cationic surfactant THA. The highest ion-pairing effi-
ciency was reached at a molar ratio of 1:8 (exenatide: THA) and pH
adjusted to 8.0 (Fig. 2). In contrast, at pH below the IP of exenatide, the
peptide bears 4 cationic substructures in its amino acid sequence at
position 1, 12, 20 and 27 being capable of forming ion pairs with the
anionic surfactant DOC. Exenatide-DOC ion pairs had the highest pre-
cipitation efficiency at a molar ratio of 1:4 (exenatide: DOC) and pH
adjusted to 3.0.
The formation of HIPs with THA and DOC was further confirmed by
a shift in zeta potential showing a clear trend to less negative values the
more THA was bound to exenatide, whereas a clear trend to less posi-
tive values the more DOC was bound to the drug (Fig. 3).
For the development of NCs, an as low as feasible concentration of
PG was used to dissolve HIPs in NCs, as this hydrophilic co-solvent is
immediately released from the lipophilic phase in aqueous media pro-
moting the release of HIPs out of the oily droplets [14]. Exenatide re-
lease from NCs was characterized based on the affinity of HIPs toward
the oily phase of NCs and the release medium [25]. A log D of at least 2
has been demanded to keep ≥ 50% of HIPs in NCs [14]. Our results
showed that exenatide-THA HIPs with a log D of 2.29 were superior to
exenatide-DOC with a log D of 1.2 in SIF. Accordingly, the amount of
exenatide immediately released from exenatide-DOC NCs is likely
higher than that from exenatide-THA NCs.
In vitro toxicity studies with human red blood cells (RBC) revealed
that both blank and loaded NCs displayed no significant hemolytic ac-
tivity at concentrations of 0.1% (m/v) and 0.25% (m/v). However, the
hemolytic activity was higher at 0.5% (m/v) of NCs confirming that this
toxicity is concentration dependent, reaching more than 70% and 90%
in exenatide-THA NCs and exenatide-DOC NCs, respectively (Fig. 4).
The concentration of 0.25% (m/v) was selected for further investiga-
tions. Exenatide-DOC NCs and exenatide-THA NCs showed a 3-fold and
10-fold enhancement in intestinal membrane permeability compared to
free exenatide (Fig. 5). The lipophilic nature of NCs and their slippery
surface in addition to a nanodroplet size of less than 30 nm are ad-
vantageous to facilitate their permeation through the intestinal mucus
gel layer and likely also across the absorption membrane [33,34]. The
composition of NCs could additionally contribute to an enhanced in-
testinal uptake of exenatide. The mixture between Capmul®MCM, a
Fig. 6. Exenatide plasma concentration vs time profiles for s.c. free exenatide solution (50 µg/kg), oral exenatide solution (dose: 300 μg/ml), oral exenatide-THA NCs
(dose: 300 μg/ml) and oral exenatide-DOC NCs (dose: 300 μg/ml). Values are presented as means ± SD (n = 5).
Table 2
Pharmacokinetic parameters of exenatide in rats following s.c. injection of the
free exenatide solution and oral administration of exenatide solution, exena-
tide-THA NCs and exenatide-DOC NCs. Cmax: maximum serum
concentration; Tmax: time at which Cmax is reached; AUC 0–10: area under the
serum concentration-time curve over 10 h, BAR: relative bioavailability (n = 5).
Formulation Free exenatide
solution
Exenatide-THA
NCs
Exenatide-DOC
NCs
Route of
administration
s.c. oral oral
Dose (µg/Kg) 50 300 300
Cmax (ng/ml) 7.0 ± 2.70 3.4 ± 0.97 1.53 ± 0.50
Tmax (h) 1 3 3
AUC 0–10 (ng h/ml) 10.56 ± 3.92 17.33 ± 3.48 10.28 ± 4.7
BAR (%) 100 27.96 ± 5.24 16.29 ± 6.63
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medium-chain mono-diglyceride, and Captex® 300, a medium-chain
triglyceride, could enhance permeation via the paracellular pathway by
opening the tight junctions while keeping the cytotoxicity at its
minimum [35,36]. Besides, in addition to its stabilizing effect as a
surfactant, Kolliphor® RH40 is an intestinal permeation enhancer
known to increase the membrane permeability [37], and it was re-
ported that it may also act as P-glycoprotein (P-gp) inhibitor [38].
Since exenatide has six anionic substructures while only four ca-
tionic ones, the lipophilicity of HIPs with the cationic counter ion THA
was assumed to be higher compared to those formed with the anionic
surfactant DOC. This assumption could be confirmed by the higher
solubility of exenatide-THA than exenatide-DOC complexes in the li-
pophilic phase. Furthermore, the higher potential of exenatide-THA
NCs in their membrane permeation behaviour (p < 0.01) is in
agreement with the higher lipophilic character of this complex. The
positive zeta potential of exenatide-THA NCs in comparison to the ne-
gatively charged exenatide-DOC NCs might also contribute to their
higher membrane permeating properties.
Recently, an enhanced oral bioavailability of exenatide up to 14.0%
versus s.c. was achieved with nanoparticles composed of chitosan and
poly (γ-glutamic acid) [30]. The results of another research group re-
ported that oral administration of the exenatide-loaded microspheres
cross-linked with alginate and hyaluronate had the potential to improve
the oral bioavailability of exenatide to 10.15% versus s.c. [6]. The re-
lative oral bioavailability elicited by oral administration of transferrin-
exenatide-Zn2+nanoparticles was 6.45% which was regarded as a
preliminary potential investigation but still needs to be further devel-
oped [39]. A recent study by our research group where exenatide was
incorporated in self-emulsifying drug delivery system after ion pairing
with DOC, showed an oral bioavailability of 14.6% [23] was obtained
after oral administration. Exenatide-THA NCs, however, showed an
even higher potential reaching a BAR of 27.96 ± 5.24% (Table 2).
These findings also show the great impact of the type of counter ions
used for HIP formation on the oral peptide bioavailability. They are in
accordance with a previous study demonstrating that the oral bioa-
vailability of octreotide strongly depends on the type of counter ion
used for HIP formation. In fact, NCs containing octreotide-deoxycholate
led to a 17.9-fold higher oral bioavailability in pigs than octreotide-
docusate HIPs [12]. Our study also revealed the potential of cationic
surfactants in increasing the lipophilicity of exenatide before being
embedded into NCs, which had a great impact on drug release char-
acteristics and intestinal permeability. The developed exenatide-THA
NCs holds high promise for oral delivery exceeding the results elicited
from preceding reported studies [6,23,30,39–43].
6. Conclusion
Within this study, the effectiveness of hydrophobic ion pairing (HIP)
of exenatide with a cationic surfactant (THA) in comparison to an an-
ionic surfactant (DOC) was investigated. Optimized HIPs were in-
corporated into NCs designed for oral delivery. Exenatide-THA NCs
demonstrated a 10-fold and 3.3-fold enhancement in intestinal ap-
parent permeability compared to free exenatide and exenatide-DOC
NCs, respectively. Following the ex vivo findings, the in vivo study in
rats proved the superiority of the cationic surfactant as the relative oral
bioavailability reached 27.96 ± 5.24% and was 1.7-fold higher than
that obtained with exenatide-DOC. Overall, this study provides sub-
stantial new insights for oral delivery of the GLP-1 analogue exenatide.
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